Novel 5-substituted pyrrolo[2,3- d ]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents

Journal of Medicinal Chemistry

Volumn 58, Issue 3, 2015, Pages 1479-1493

  Wang, Yiqiang ^a,d   Mitchell Ryan, Shermaine ^c   Raghavan, Sudhir ^a   George, Christina ^b   Orr, Steven ^b   Hou, Zhanjun ^b,c   Matherly, Larry H ^b,c   Gangjee, Aleem ^a  

^a DUQUESNE UNIVERSITY   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE DERIVATIVE; ADENOSINE; ANTINEOPLASTIC AGENT; FOLATE RECEPTOR 1; FOLIC ACID ANTAGONIST; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; PROTON COUPLED FOLATE TRANSPORTER; PURINE NUCLEOTIDE; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; REDUCED FOLATE CARRIER; THYMIDINE; ENZYME INHIBITOR; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; PYRROLO(2,3-D)PYRIMIDINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACCUMULATION; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; IC50; KB CELL LINE; MOLECULAR MODEL; NONHUMAN; PURINE SYNTHESIS; STABLE EXPRESSION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELLS, CULTURED; CHO CELLS; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; KB CELLS; MOLECULAR STRUCTURE; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PYRIMIDINES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84922778207     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501787c     Document Type: Article

References (47)

1. Gonen, N.; Assaraf, Y. G. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance Drug Resist. Updates 2012, 15, 183-210
2. Visentin, M.; Zhao, R.; Goldman, I. D. The antifolates Hematol. Oncol. Clin. North Am. 2012, 26, 629-48
3. Chattopadhyay, S.; Moran, R. G.; Goldman, I. D. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Mol. Cancer Ther. 2007, 6, 404-17
4. Boritzki, T. J.; Barlett, C. A.; Zhang, C.; Howland, E. F. AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase Invest. New Drugs 1996, 14, 295-303
5. Budman, D. R.; Johnson, R.; Barile, B.; Bowsher, R. R.; Vinciguerra, V.; Allen, S. L.; Kolitz, J.; Ernest, C. S., 2nd; Kreis, W.; Zervos, P.; Walling, J. Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis Cancer Chemother. Pharmacol. 2001, 47, 525-31
6. Mendelsohn, L. G.; Worzalla, J. F.; Walling, J. M. Preclinical and clinical evaluation of the glycinamide ribonucleotide formyltransferase inhibitors lometrexol and LY309887. In Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press, Inc.: Totowa, NJ, 1999; pp 261-280.
7. Ray, M. S.; Muggia, F. M.; Leichman, C. G.; Grunberg, S. M.; Nelson, R. L.; Dyke, R. W.; Moran, R. G. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis J. Natl. Cancer Inst. 1993, 85, 1154-9
8. Matherly, L. H.; Wilson, M. R.; Hou, Z. The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer Drug Metab. Dispos. 2014, 42, 632-49
9. Desmoulin, S. K.; Hou, Z.; Gangjee, A.; Matherly, L. H. The human proton-coupled folate transporter: biology and therapeutic applications to cancer Cancer Biol. Ther. 2012, 13, 1355-73
10. Elnakat, H.; Ratnam, M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy Adv. Drug Delivery Rev. 2004, 56, 1067-84
11. Zhao, R.; Matherly, L. H.; Goldman, I. D. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues Expert Rev. Mol. Med. 2009, 11, e4
12. Salazar, M. D.; Ratnam, M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 2007, 26, 141-52
13. Xia, W.; Low, P. S. Folate-targeted therapies for cancer J. Med. Chem. 2010, 53, 6811-24
14. Kugel Desmoulin, S.; Wang, L.; Hales, E.; Polin, L.; White, K.; Kushner, J.; Stout, M.; Hou, Z.; Cherian, C.; Gangjee, A.; Matherly, L. H. Therapeutic targeting of a novel 6-substituted pyrrolo [2,3- d ]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter Mol. Pharmacol. 2011, 80, 1096-107
15. Armstrong, D. K.; White, A. J.; Weil, S. C.; Phillips, M.; Coleman, R. L. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer Gynecol. Oncol. 2013, 129, 452-8
16. Reddy, J. A.; Dorton, R.; Bloomfield, A.; Nelson, M.; Vetzel, M.; Guan, J.; Leamon, C. P. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs Clin. Cancer Res. 2014, 20, 2104-14
17. Reddy, J. A.; Dorton, R.; Westrick, E.; Dawson, A.; Smith, T.; Xu, L. C.; Vetzel, M.; Kleindl, P.; Vlahov, I. R.; Leamon, C. P. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate Cancer Res. 2007, 67, 4434-42
18. Gibbs, D. D.; Theti, D. S.; Wood, N.; Green, M.; Raynaud, F.; Valenti, M.; Forster, M. D.; Mitchell, F.; Bavetsias, V.; Henderson, E.; Jackman, A. L. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors Cancer Res. 2005, 65, 11721-8
19. Deng, Y.; Wang, Y.; Cherian, C.; Hou, Z.; Buck, S. A.; Matherly, L. H.; Gangjee, A. Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity J. Med. Chem. 2008, 51, 5052-63
20. Wang, L.; Cherian, C.; Desmoulin, S. K.; Polin, L.; Deng, Y.; Wu, J.; Hou, Z.; White, K.; Kushner, J.; Matherly, L. H.; Gangjee, A. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3- d ]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry J. Med. Chem. 2010, 53, 1306-18
21. Wang, L.; Kugel Desmoulin, S.; Cherian, C.; Polin, L.; White, K.; Kushner, J.; Fulterer, A.; Chang, M. H.; Mitchell-Ryan, S.; Stout, M.; Romero, M. F.; Hou, Z.; Matherly, L. H.; Gangjee, A. Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3- d ]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits beta-glycinamide ribonucleotide formyltransferase J. Med. Chem. 2011, 54, 7150-64
22. Cherian, C.; Kugel Desmoulin, S.; Wang, L.; Polin, L.; White, K.; Kushner, J.; Stout, M.; Hou, Z.; Gangjee, A.; Matherly, L. H. Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3- d ]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter Cancer Chemother. Pharmacol. 2013, 71, 999-1011
23. Kugel Desmoulin, S.; Wang, L.; Polin, L.; White, K.; Kushner, J.; Stout, M.; Hou, Z.; Cherian, C.; Gangjee, A.; Matherly, L. H. Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter Mol. Pharmacol. 2012, 82, 591-600
24. Kugel Desmoulin, S.; Wang, Y.; Wu, J.; Stout, M.; Hou, Z.; Fulterer, A.; Chang, M. H.; Romero, M. F.; Cherian, C.; Gangjee, A.; Matherly, L. H. Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3- d ]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors Mol. Pharmacol. 2010, 78, 577-87
25. Deng, Y.; Zhou, X.; Kugel Desmoulin, S.; Wu, J.; Cherian, C.; Hou, Z.; Matherly, L. H.; Gangjee, A. Synthesis and biological activity of a novel series of 6-substituted thieno[2,3- d ]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry J. Med. Chem. 2009, 52, 2940-51
26. Shih, C.; Thornton, D. E. Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514). In Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press, Inc.: Totowa, NJ, 1999; pp 183-201.
27. Racanelli, A. C.; Rothbart, S. B.; Heyer, C. L.; Moran, R. G. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition Cancer Res. 2009, 69, 5467-74
28. Rothbart, S. B.; Racanelli, A. C.; Moran, R. G. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas Cancer Res. 2010, 70, 10299-309
29. Wang, Y.; Cherian, C.; Orr, S.; Mitchell-Ryan, S.; Hou, Z.; Raghavan, S.; Matherly, L. H.; Gangjee, A. Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3- d ]pyrimidine antifolates via cellular uptake by folate receptor alpha and inhibition of de novo purine nucleotide biosynthesis J. Med. Chem. 2013, 56, 8684-95
30. Golani, L. K.; George, C.; Zhao, S.; Raghavan, S.; Orr, S.; Wallace, A.; Wilson, M. R.; Hou, Z.; Matherly, L. H.; Gangjee, A. Structure-activity profiles of novel 6-substituted pyrrolo[2,3- d ]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter J. Med. Chem. 2014, 57, 8152-66
31. Mitchell-Ryan, S.; Wang, Y.; Raghavan, S.; Ravindra, M. P.; Hales, E.; Orr, S.; Cherian, C.; Hou, Z.; Matherly, L. H.; Gangjee, A. Discovery of 5-substituted pyrrolo[2,3- d ]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity J. Med. Chem. 2013, 56, 10016-32
32. Kumar, V. P.; Cisneros, J. A.; Frey, K. M.; Castellanos-Gonzalez, A.; Wang, Y.; Gangjee, A.; White, A. C., Jr.; Jorgensen, W. L.; Anderson, K. S. Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase Bioorg. Med. Chem. Lett. 2014, 24, 4158-61
33. Aso, K.; Imai, Y.; Yukishige, K.; Ootsu, K.; Akimoto, H. Pyrrolo[2,3- d ]pyrimidine thymidylate synthase inhibitors: design and synthesis of one-carbon bridge derivatives Chem. Pharm. Bull. 2001, 49, 1280-7
34. Barnett, C. J.; W, T. M.; Kobierski, M. E. A practical synthesis of multitargeted antifolate LY231514 Org. Process Res. Dev 1999, 3, 184-188
35. Bloch, R. 5,5-Dibromo-2,2-dimethyl-4,6-dioxo-1,3-dioxane-new brominating agent for saturated and β-unsaturated carbonyl-compounds Synthesis 1978, 140-142
36. Wong, S. C.; Proefke, S. A.; Bhushan, A.; Matherly, L. H. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells J. Biol. Chem. 1995, 270, 17468-75
37. Flintoff, W. F.; Nagainis, C. R. Transport of methotrexate in Chinese hamster ovary cells: a mutant defective in methotrexate uptake and cell binding Arch. Biochem. Biophys. 1983, 223, 433-40
38. Connelly, S.; DeMartino, J. K.; Boger, D. L.; Wilson, I. A. Biological and structural evaluation of 10 R-and 10 S -methylthio-DDACTHF reveals a new role for sulfur in inhibition of glycinamide ribonucleotide transformylase Biochemistry 2013, 52, 5133-44
39. Cheong, C. G.; Wolan, D. W.; Greasley, S. E.; Horton, P. A.; Beardsley, G. P.; Wilson, I. A. Crystal structures of human bifunctional enzyme aminoimidazole-4-carboxamide ribonucleotide transformylase/IMP cyclohydrolase in complex with potent sulfonyl-containing antifolates J. Biol. Chem. 2004, 279, 18034-45
40. Chen, C.; Ke, J.; Zhou, X. E.; Yi, W.; Brunzelle, J. S.; Li, J.; Yong, E. L.; Xu, H. E.; Melcher, K. Structural basis for molecular recognition of folic acid by folate receptors Nature 2013, 500, 486-9
41. LeadIT2.1, St. Augustin, Germany.
42. Zhang, Y.; Desharnais, J.; Marsilje, T. H.; Li, C.; Hedrick, M. P.; Gooljarsingh, L. T.; Tavassoli, A.; Benkovic, S. J.; Olson, A. J.; Boger, D. L.; Wilson, I. A. Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid Biochemistry 2003, 42, 6043-56
43. Wibowo, A. S.; Singh, M.; Reeder, K. M.; Carter, J. J.; Kovach, A. R.; Meng, W.; Ratnam, M.; Zhang, F.; Dann, C. E., III. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 15180-8
44. Molecular Operating Environment (MOE), 1010 Sherbrooke St. W., Suite 910, Montreal, QC, Canada H3A 2R7, 2011.
45. McNicholas, S.; Potterton, E.; Wilson, K. S.; Noble, M. E. Presenting your structures: the CCP4mg molecular-graphics software Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 386-94
46. Huang, D.; Zhang, Y.; Chen, X. Analysis of intracellular nucleoside triphosphate levels in normal and tumor cell lines by high-performance liquid chromatography J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2003, 784, 101-9
47. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent J. Biol. Chem. 1951, 193, 265-75